Carderock Capital Management Inc. raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.2% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 33,333 shares of the medical research company’s stock after buying an additional 4,143 shares during the quarter. Thermo Fisher Scientific comprises about 2.8% of Carderock Capital Management Inc.’s holdings, making the stock its 6th largest position. Carderock Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $6,307,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of Thermo Fisher Scientific by 4.6% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 16,485 shares of the medical research company’s stock worth $3,120,000 after purchasing an additional 732 shares in the last quarter. Beacon Investment Advisory Services Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth $422,000. Highbridge Capital Management LLC purchased a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth $2,122,000. Laurel Wealth Advisors Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth $214,000. Finally, Bank of Nova Scotia Trust Co. purchased a new stake in shares of Thermo Fisher Scientific in the 3rd quarter worth about $106,000. 86.05% of the stock is currently owned by institutional investors.
Several research firms recently commented on TMO. Leerink Swann reiterated an “outperform” rating and issued a $200.00 price objective (down from $216.00) on shares of Thermo Fisher Scientific in a research report on Monday, December 4th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 price objective on the stock in a research report on Tuesday, October 31st. Deutsche Bank set a $226.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Thursday, October 26th. Jefferies Group reiterated a “hold” rating and issued a $195.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, September 28th. Finally, Goldman Sachs Group began coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, September 26th. They issued a “buy” rating and a $225.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $205.21.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.24 by $0.07. The company had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The firm’s quarterly revenue was up 13.9% on a year-over-year basis. During the same period in the prior year, the firm earned $2.03 EPS. equities research analysts predict that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be issued a $0.15 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a yield of 0.31%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.19%.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $191.74, for a total value of $9,587,000.00. Following the transaction, the chief executive officer now directly owns 302,577 shares in the company, valued at approximately $58,016,113.98. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.49% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Carderock Capital Management Inc. Has $6.31 Million Holdings in Thermo Fisher Scientific Inc. (TMO)” was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.com-unik.info/2017/12/22/carderock-capital-management-inc-has-6-31-million-holdings-in-thermo-fisher-scientific-inc-tmo.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.